Browse our press packs

A decade-long analysis reveals potential bottlenecks in the pathway of clinical research into medical practice.

PLATCOV, a platform to assess the effectiveness of drugs against COVID-19, suggests that ivermectin has no significant antiviral activity against SARS-CoV-2.

Just one or two mutations with strong effects, or an accumulation of mutations with small effects, may help the Omicron variant of SARS-CoV-2 dodge the immune system or antibody-based therapies.

The expanded service will provide biophysicists with a new way of validating their research.

High-profile news coverage that eLife papers generated in January 2023, including The Washington Post, The New York Times and Earth.com.

When deciding on responses to a new stimulus, slower initial response times can maximise long-term reward through learning.

An analysis of cancer diagnosis and treatment highlights inconsistencies in the way lag times are calculated and suggests more standardised approaches are needed.

Drug resistance to aminoglycosides, a class of antibiotics, may be driven more by exchanges between ecosystems than by drug consumption.

Infection with a common bacteria linked with periodontal disease, oral cancers, and bad breath may cause a small increase in the risk of cardiovascular disease.

A follow-up study of cancer patients after COVID-19 suggests that one in two experienced long COVID, but few required hospital admission and most could be managed as outpatients.